ICON Public (NASDAQ:ICLR) Given New $203.00 Price Target at Robert W. Baird

ICON Public (NASDAQ:ICLR) had its target price dropped by equities researchers at Robert W. Baird from $221.00 to $203.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has a “neutral” rating on the medical research company’s stock. Robert W. Baird’s price objective indicates a potential upside of 11.26% from the company’s previous close.

A number of other research analysts also recently issued reports on the stock. Truist Financial reduced their price target on shares of ICON Public from $284.00 to $262.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Royal Bank of Canada reissued an “outperform” rating and issued a $263.00 target price on shares of ICON Public in a report on Wednesday, January 15th. Leerink Partners reaffirmed an “outperform” rating and set a $255.00 target price (down from $270.00) on shares of ICON Public in a report on Tuesday, November 19th. Barclays cut their price target on ICON Public from $275.00 to $240.00 and set an “overweight” rating on the stock in a report on Friday, February 21st. Finally, William Blair restated an “outperform” rating on shares of ICON Public in a research note on Tuesday, January 14th. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $279.17.

ICON Public Stock Down 1.3 %

NASDAQ:ICLR opened at $182.45 on Tuesday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.34 and a current ratio of 1.26. The company has a market capitalization of $14.73 billion, a price-to-earnings ratio of 19.16, a price-to-earnings-growth ratio of 1.86 and a beta of 1.19. ICON Public has a one year low of $179.50 and a one year high of $347.72. The stock has a 50-day simple moving average of $201.37 and a 200 day simple moving average of $239.26.

ICON Public (NASDAQ:ICLR) last issued its earnings results on Wednesday, February 19th. The medical research company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.41 by $0.01. The company had revenue of $2.04 billion during the quarter, compared to analyst estimates of $2.04 billion. ICON Public had a return on equity of 11.81% and a net margin of 9.56%. Sell-side analysts predict that ICON Public will post 13.38 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Foyston Gordon & Payne Inc grew its stake in ICON Public by 27.3% during the 4th quarter. Foyston Gordon & Payne Inc now owns 51,713 shares of the medical research company’s stock valued at $10,845,000 after acquiring an additional 11,089 shares in the last quarter. Captrust Financial Advisors boosted its holdings in shares of ICON Public by 2.0% during the fourth quarter. Captrust Financial Advisors now owns 35,301 shares of the medical research company’s stock worth $7,403,000 after purchasing an additional 701 shares during the period. State of Tennessee Department of Treasury grew its position in ICON Public by 1.0% during the fourth quarter. State of Tennessee Department of Treasury now owns 158,947 shares of the medical research company’s stock valued at $33,333,000 after purchasing an additional 1,600 shares in the last quarter. Motley Fool Wealth Management LLC increased its stake in ICON Public by 2.3% in the 4th quarter. Motley Fool Wealth Management LLC now owns 64,038 shares of the medical research company’s stock valued at $13,342,000 after buying an additional 1,466 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. lifted its position in ICON Public by 128.2% in the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 1,166 shares of the medical research company’s stock worth $245,000 after buying an additional 655 shares in the last quarter. 95.61% of the stock is owned by institutional investors and hedge funds.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.